Aging With HIV and Neurocognitive Decline, a Follow-up Study

Prior treatment

• With recent extensive neurocognitive evaluation within 6 months prior to inclusion

Other illness

• An Isolated HIV-2 infection
• Confused or with an ongoing neurological disease
• Presenting psychiatric syndromes interfering with cognitive evaluation;
• With neurological disease with ongoing clinically relevant sequela

Other

• Non-inclusion criteria for PLHIV for both the longitudinal and transversal studies:
• With sensorial loss, analphabetism or language barriers rendering the interpretation of tests difficult.
• Participating in another research program, prohibiting the participating in additional research
• Vulnerable: minors, under guardianship or curatorship, or persons deprived of liberty for administrative or judiciary reasons

• Having participated in the ANRS EP58 HAND 55-70 study
• A signed informed consent
• To be affiliated and benefit from the French Social Security
• HIV-1
• Aged between 55 years and 76 years;
• with a viral load \< 50 copies/mL for more than 24 months (with a minimum of 3 available viral loads 6 months prior to inclusion). Blips -defined by a transient increase in viral load- are allowed if \< 200 copies/mL, with a maximum of two blips within 24 months;
• With a CD4 (cluster of differentiation 4) count at inclusion ≥ 200 cells/µL for more than the last 12 months (with a last available CD4 count \< 6 months of inclusion);
• A signed informed consent
• To be affiliated and benefit from the French Social Security